Literature DB >> 7718264

Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line.

B S Andersson1, M Mroue, R A Britten, D Farquhar, D Murray.   

Abstract

The 4-hydroperoxycyclophosphamide (4HC)-resistant B5-180(3) subline of the cloned KBM-7/B5 cell line was developed as a model of induced cyclophosphamide resistance in human myeloid leukemia. Based on IC90 values, this subline was approximately 20-fold resistant to 4HC. Furthermore, it was significantly cross-resistant to phosphorodiamidic mustard (PM), whose cytotoxicity is independent of aldehyde dehydrogenase (ADH). Using alkaline elution we found that the resistant line had decreased initial levels of DNA interstrand cross-links (ISCs) following 4HC but not PM treatment. The resistant cells also appeared to remove ISCs from their DNA more rapidly than the parental cells. Our data therefore suggest that 4HC resistance in the B5-180(3) subline is multifactorial; ADH is an important mediator of its resistance to ISC induction by 4HC, while a second process, which may involve an increased ability to tolerate drug-induced DNA damage, appears to be important for its resistance to both 4HC and PM. The B5-180(3) cells were also cross-resistant to gamma-radiation (approximately 1.7-fold at a surviving fraction of 0.1); if generally applicable, such effects could have important clinical implications, since pretransplant total body irradiation is a major component of the eradication of leukemic cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7718264     DOI: 10.3109/02841869509093963

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  3 in total

1.  Cyclophosphamides as hypoxia-activated diffusible cytotoxins: a theoretical study.

Authors:  J H Wu; C A Reynolds
Journal:  J Comput Aided Mol Des       Date:  2000-05       Impact factor: 3.686

2.  Identification of potential genes associated with ALDH1A1 overexpression and cyclophosphamide resistance in chronic myelogenous leukemia using network analysis.

Authors:  Gera Narendra; Baddipadige Raju; Himanshu Verma; Om Silakari
Journal:  Med Oncol       Date:  2021-09-07       Impact factor: 3.064

3.  Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1.

Authors:  Maura Gasparetto; Shanshan Pei; Mohammad Minhajuddin; Nabilah Khan; Daniel A Pollyea; Jason R Myers; John M Ashton; Michael W Becker; Vasilis Vasiliou; Keith R Humphries; Craig T Jordan; Clayton A Smith
Journal:  Haematologica       Date:  2017-03-09       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.